Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Aurobindo Pharma has informed that – The United States Food and Drug Administration (USFDA) inspected Unit-VI, an API manufacturing facility of Apitoria Pharma, a wholly owned subsidiary of the Company, situated at E-Bonangi Village, Parawada Mandal, Anakapalli District, 531019, Andhra Pradesh from August 24 to August 28, 2026, and concluded with three observations. The Unit has now received Establishment Inspection Report (EIR), classifying the facility as ‘Voluntary Action Indicated’ (‘VAI’). The USFDA has concluded that this inspection is now closed.
The above information is a part of company’s filings submitted to BSE.